Activation of aryl hydrocarbon receptor by TCDD prevents diabetes in NOD mice and increases Foxp3+ T cells in pancreatic lymph nodes - PubMed (original) (raw)

Activation of aryl hydrocarbon receptor by TCDD prevents diabetes in NOD mice and increases Foxp3+ T cells in pancreatic lymph nodes

Nancy I Kerkvliet et al. Immunotherapy. 2009 Jul.

Abstract

The ligand-activated transcription factor, aryl hydrocarbon receptor (AHR), is a novel inducer of adaptive Tregs. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD), the most potent AHR ligand, induces adaptive CD4+CD25+ Tregs during an acute graft-versus-host (GvH) response and prevents the generation of allospecific cytotoxic T lymphocytes. TCDD also suppresses the induction of experimental autoimmune encephalitis in association with an expanded population of Foxp3+ Tregs. In this study, we show that chronic treatment of NOD mice with TCDD potently suppresses the development of autoimmune Type 1 diabetes in parallel with greatly reduced pancreatic islet insulitis and an expanded population of CD4+CD25+Foxp3+ cells in the pancreatic lymph nodes. When treatment with TCDD was terminated after 15 weeks (23 weeks of age), mice developed diabetes over the next 8 weeks in association with lower numbers of Tregs and decreased activation of AHR. Analysis of the expression levels of several genes associated with inflammation, T-cell activation and/or Treg function in pancreatic lymph node cells failed to reveal any differences associated with TCDD treatment. Taken together, the data suggest that AHR activation by TCDD-like ligands may represent a novel avenue for treatment of immune-mediated diseases.

Keywords: 2,3,7,8-tetrachlorodibenzo-p-dioxin; AHR; NOD mice; TCDD; Type 1 diabetes; aryl hydrocarbon receptor; regulatory T cell.

PubMed Disclaimer

Figures

Figure 1

Figure 1. Sequence analysis of exon 10 of AHR gene in NOD mice shows a low-affinity AHRd haplotype identical to that found in DBA/2 mice

AHR: Aryl hydrocarbon receptor; NOD: Nonobese diabetic. Data adapted from [13].

Figure 2

Figure 2. Treatment of NOD mice with TCDD results in sustained activation of AHR as evidenced by a high level of hepatic Cyp1a1 message at 31 weeks of age

Aryl hydrocarbon receptor (AHR) activation declines when TCDD treatment is terminated and is no longer apparent after 8 weeks of VEH treatment. NOD mice were dosed orally biweekly with VEH or TCDD until 31 weeks of age. At 23 weeks of age, half of the TCDD-treated mice were switched to VEH for the remaining 8 weeks. Liver samples were obtained from mice that survived to 31 weeks and processed for RNA. Cyp1a1 expression data represent fold-change relative to β-actin message from three, 12 and three mice in VEH, TCDD and TCDD/VEH groups, respectively. NOD: Nonobese diabetic; TCDD: 2,3,7,8-tetrachlorodibenzo-p-dioxin; VEH: Vehicle.

Figure 3

Figure 3. TCDD-treated mice are protected from diabetes by continuous treatment with TCDD

Groups of mice were treated with VEH (n = 11) or TCDD (n = 12) biweekly, beginning at 8 weeks of age. With no diabetes in any of the TCDD-treated mice at 23 weeks of age, half of the mice in the TCDD-treatment group were switched to VEH for the remainder of the study (TCDD/VEH). Blood glucose levels were measured weekly. Animals were terminated by an overdose of CO2 when nonfasting blood glucose level exceeded 250 mg/dl for 2 consecutive days. TCDD: 2,3,7,8-tetrachlorodibenzo-p-dioxin; VEH: Vehicle.

Figure 4

Figure 4. NOD mice treated biweekly with TCDD from 8 to 15 weeks of age show greatly reduced insulitis

Groups of 12 mice were treated with VEH or TCDD. At 15 weeks of age, pancreata were frozen in optimal cutting temperature compound. A minimum of five 5 μm pancreatic sections, each 200 μm apart, were cut for each tissue block. Sections were fixed in formalin and stained with hematoxylin and eosin for visualization and scoring of individual islets. Data reflect scores from four representative nondiabetic mice per treatment. NOD: Nonobese diabetic; TCDD: 2,3,7,8-tetrachlorodibenzo-p-dioxin; VEH: Vehicle.

Figure 5

Figure 5. Frequency of CD4 +CD25+Foxp3+ T cells in the pancreatic lymph nodes is increased in NOD mice treated biweekly with TCDD until 31 weeks of age

Mice removed from TCDD treatment 8 weeks earlier no longer show elevated frequency of CD4+CD25+ Foxp3+ T cells. Data represent mean ± SEM of three, 12 and three mice in VEH, TCDD and TCDD/VEH groups, respectively. Cells were stained for flow cytometric analysis as described in Materials and Methods. NOD: Nonobese diabetic; TCDD: 2,3,7,8-tetrachlorodibenzo-p-dioxin; VEH: Vehicle.

Similar articles

Cited by

References

    1. Funatake CJ, Marshall NB, Steppan LB, Mourich DV, Kerkvliet NI. Cutting edge: activation of the aryl hydrocarbon receptor by 2,3,7,8-tetrachlorodibenzo-p-dioxin generates a population of CD4+ CD25+ cells with characteristics of regulatory T cells. J Immunol. 2005;175:4184–4188. First demonstration and initial characterization of a CD4+CD25+ T regulatory (Treg)-like cell induced by engagement of aryl hydrocarbon receptor (AhR) via 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) treatment. - PubMed
    1. Funatake CJ, Marshall NB, Kerkvliet NI. 2,3,7,8-tetrachlorodibenzo-p-dioxin alters the differentiation of alloreactive CD8+ T cells toward a regulatory T cell phenotype by a mechanism that is dependent on aryl hydrocarbon receptor in CD4+ T cells. J Immunotoxicol. 2008;5:81–91. First paper to exhibit AHR-dependent effects on CD8+ differentiation into a regulatory phenotype induced by TCDD. - PubMed
    1. Marshall NB, Vorachek WR, Steppan LB, Mourich DV, Kerkvliet NI. Functional characterization and gene expression analysis of CD4+ CD25+ regulatory T cells generated in mice treated with 2,3,7,8-tetrachlorodibenzo-p-dioxin. J Immunol. 2008;181:2382–2391. Extensive phenotypic and functional characterization of the novel subset of CD4+ Tregs induced by TCDD compared to conventional Tregs, including expression of Foxp3 and a role for IL-12R. - PMC - PubMed
    1. Quintana FJ, Basso AS, Iglesias AH, et al. Control of Treg and Th17 cell differentiation by the aryl hydrocarbon receptor. Nature. 2008;453:65–71. First report demonstrating a differential role for different AHR ligands in the suppression or exacerbation of experimental autoimmune encephalomyelitis through the induction of Tregs versus Th17, respectively. Concurrent companion publication along with [28] - PubMed
    1. Kerkvliet NI, Shepherd DM, Baecher-Steppan L. T lymphocytes are direct, aryl hydrocarbon receptor (AhR)-dependent targets of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD): AhR expression in both CD4+ and CD8+ T cells is necessary for full suppression of a cytotoxic T lymphocyte response by TCDD. Toxicol Appl Pharmacol. 2002;185:146–152. - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources